Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma

14 Jan 2015

Abstract excerpt

MGMT promoter methylation status is a strong and independent prognostic factor in patients with newly diagnosed glioblastoma and a clinically relevant predictive marker in the subpopulation of elderly glioblastoma patients. However, there is still lack of consensus on the optimal assay for reliable MGMT promoter methylation testing and a variety of test are being used in different laboratories. Pyrosequencing is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25586425
DOI: 10.2217/cns.14.50

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastomaPMID 25586425Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

Predictive impact of <i>MGMT</i> promoter methylation in glioblastoma of the elderlySemantic proximity Read ↗

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaSemantic proximity Read ↗

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity Read ↗

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme.Semantic proximity Read ↗

Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusSemantic proximity Read ↗

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudySemantic proximity Read ↗

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Semantic proximity Read ↗

Validation of the high-performance of pyrosequencing for clinical <i>MGMT</i> testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trialSemantic proximity Read ↗

Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastomaSemantic proximity Read ↗

Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastomaSemantic proximity Read ↗

MGMT Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in GlioblastomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.